Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting state Clear all
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 20, 2026, 11:27 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

NCT02184585
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 20, 2026, 11:27 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls

NCT07857837
View directory record Official record
Conditions
Renal Impairment
Interventions
Sulthiame
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Altamonte Springs, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed No phase listed Observational

Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes

NCT00287404
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of North Carolina
Other
Eligibility
20 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

NCT07613684
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD
Drug
Lead sponsor
Epirium Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Marlton, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

NCT04939467
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet
Drug
Lead sponsor
Blade Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 2 Interventional Results available

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Esomeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 20, 2026, 11:27 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults

NCT07572266
View directory record Official record
Conditions
Aging, Aging Well, Healthy Aging
Interventions
Nitrate enriched beetroot juice, Nitrate depleted beetroot juice, 12 week of combined exercise training
Dietary Supplement · Other
Lead sponsor
Florida Institute for Human and Machine Cognition
Other
Eligibility
60 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

NCT05330858
View directory record Official record
Conditions
Pharmacokinetics
Interventions
ESK-001, Rabeprazole
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

NCT05457270
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD4831
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 20, 2026, 11:27 PM EDT
Terminated Phase 2 Interventional

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

NCT02525302
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
HT-100
Drug
Lead sponsor
Akashi Therapeutics
Industry
Eligibility
6 Years to 20 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Prasugrel in Healthy Participants

NCT01648790
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Prasugrel ODT1 - Tablet, Prasugrel ODT2 - Tablet, Prasugrel ODT2 - Suspension
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 20, 2026, 11:27 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

NCT04898907
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Baxdrostat Bioavailability and Bioequivalence Study

NCT05963009
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat (formerly CIN-107) oral solution
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

NCT05781399
View directory record Official record
Conditions
Phenylketonuria
Interventions
JNT-517 Suspension, Placebo Suspension, JNT-517 Tablet, Placebo Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
11
States / cities
Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

NCT01716897
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

NCT03290443
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
40 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY4268989 (MORF-057) in Healthy Participants

NCT06964776
View directory record Official record
Conditions
Healthy
Interventions
LY4268989, Placebo, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 20, 2026, 11:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

NCT03082235
View directory record Official record
Conditions
Healthy Participants
Interventions
E6742, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 20, 2026, 11:27 PM EDT